What's in Altacor Ltd.'s pipeline?

Altacor Ltd. has 2 drugs in our index: 0 marketed, 0 filed, 2 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Altacor Ltd.'s portfolio?

Top competitors by shared drug class: Marin L. Schweizer, PhD.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/altacor-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Altacor Ltd. — Portfolio Competitive Intelligence Brief

Altacor Ltd. pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Betadine ophthalmic prep solution	Betadine ophthalmic prep solution	phase 3	Topical antiseptic/antimicrobial	Microbial proteins and nucleic acids (non-selective oxidative mechanism)	Ophthalmology / Infection Prevention
ALT005 Ophthalmic Prep Solution	ALT005 Ophthalmic Prep Solution	phase 3			Ophthalmology

Therapeutic area mix

Ophthalmology · 1
Ophthalmology / Infection Prevention · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Marin L. Schweizer, PhD · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Altacor Ltd.:

Cite this brief

Drug Landscape (2026). Altacor Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/altacor-ltd. Accessed 2026-05-14.